Nemaura Announces Open-Source Software for its Continuous Glucose Monitor SugarBEAT®
May 02 2019 - 9:00AM
– Nemaura Medical, Inc.
(NASDAQ: NMRD), a medical technology company
focused on the development of SugarBEAT® as a non-invasive,
affordable and flexible Continuous Glucose Monitor (CGM) for use by
diabetics and pre-diabetics, today announced it will allow
third-party applications, such as diabetes management, exercise and
nutrition focused apps royalty free access to SugarBEAT® CGM
app data. As a result, users will be able to directly access
SugarBEAT® generated glucose data through their preferred
participating mobile aplications, empowering users with greater
choice over when to use this data to better understand how food
choices and other lifestyle factors impact glucose levels.
This development is part of the Company’s broader go-to-market
strategy, which is being led by Dr. Fred Schaebsdau. Dr.
Schaebsdau joined the Company earlier this year to advance the
commercialization and business development of SugarBEAT®, building
on his success with earlier CGM products at Abbott Diabetes Care
and Dexcom Germany.”
Dr. Schaebsdau commented, “We believe integrating SugarBEAT®
data into the leading health and fitness apps will help to expand
our target market among health-conscious consumers, providing them
with seamless access to their CGM data within a familiar
environment, which will assist in understanding how diet, sleep,
stress, exercise and other lifestyle factors can impact glucose
levels. Given SugarBEAT® is non-invasive, we believe it is uniquely
placed amongst CGMs to appeal to the health-conscious consumer
market. ”
Dr. Faz Chowdhury, CEO of Nemaura, commented, “We expect this
integration will also benefit diabetics and pre-diabetics by making
it easier for them to access CGM data through their preferred
diabetes, fitness or wellness App as well as providing insurers,
healthcare providers, and fitness coaches with new tools to help
their patients and clients keep their glucose levels in normal
range for longer.”
To view a video of SugarBEAT®, please visit
http://sugarbeat.com/introducing-sugarbeat/
About Nemaura Medical, Inc.:
Nemaura Medical, Inc. (NASDAQ: NMRD), is a medical technology
company developing SugarBEAT® as a non-invasive, affordable and
flexible Continuous Glucose Monitor (CGM) designed to help people
with diabetes and pre-diabetics better manage their glucose levels
by spending more time in range. Insulin users can adjunctively use
SugarBEAT® when calibrated by a finger stick reading. SugarBEAT®
consists of a daily, disposable adhesive skin-patch connected to a
small form factor rechargeable transmitter, connected via Bluetooth
to a specially designed mobile application, which displays glucose
readings at five-minute intervals throughout the day.
For more information visit:
www.NemauraMedical.com
www.SugarBEAT.com
Cautionary Statement Regarding Forward Looking
Statements:
The statements in this press release that are not historical
facts, and may constitute forward-looking statements that are based
on current expectations and are subject to risks and uncertainties
that could cause actual future results to differ materially from
those expressed or implied by such statements. Those risks and
uncertainties include, but are not limited to, risks related to
regulatory approvals and the success of Nemaura’s ongoing studies,
including the safety and efficacy of Nemaura’s SugarBEAT® system,
the failure of future development and preliminary marketing
efforts, Nemaura’s ability to secure additional commercial
partnering arrangements, risks and uncertainties relating to
Nemaura and its partners’ ability to develop, market and sell
SugarBEAT®, the availability of substantial additional equity or
debt capital to support its research, development and product
commercialization activities, and the success of its research,
development, regulatory approval, marketing and distribution plans
and strategies, including those plans and strategies related to
SugarBEAT®. These and other risks and uncertainties are identified
and described in more detail in Nemaura’s filings with the
Securities and Exchange Commission, including, without limitation,
its Annual Report on Form 10-K for the current year, its Quarterly
Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura
undertakes no obligation to publicly update or revise any
forward-looking statements.
Contact:
Crescendo Communications, LLC 212-671-1021
NMRD@crescendo-ir.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Sep 2023 to Sep 2024